Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Titel:
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Auteur:
Bringhen, Sara Cani, Lorenzo Antonioli, Elisabetta Derudas, Daniele Fazio, Francesca Larocca, Alessandra Ronconi, Sonia Cellini, Claudia Falcone, Antonietta Pia Accardi, Fabrizio Liberati, Anna Marina Galieni, Piero Belotti, Angelo Cafro, Anna Maria Ria, Roberto Benevolo, Giulia Vincelli, Iolanda Donatella Mannina, Donato Lotti, Flavia Bruno, Benedetto Marasco, Vincenzo Mazza, Rita Tosi, Patrizia Rivolti, Elena Boccadoro, Mario D’Agostino, Mattia